Transformational Combination Creates a Leading Regenerative Medicine Company Across Numerous Surgical Subspecialties Accelerates MIMEDX’s Strategi...
Q2 sales growth of 17.8% at CER1 and business earnings per share (EPS)2 of €2.09 Pharma launches sales increased by 48.3%, reaching €1.3 bil...
“We delivered outstanding performance in the second quarter, reflecting the strength of our proven growth strategy, our team’s excellen...
Danaher Corporation announced results for the second quarter 2026. All results in this release reflect only continuing operations and period-to-per...
In H1 2026, Lonza1 delivered sales of CHF 3.4 billion with +16.0% CER2 sales growth The CORE EBITDA margin significantly expanded by +4.4...
Delivers strong Q2 results and raises FY26 revenue growth, margin expansion, and non-GAAP EPS(4) guidance on continued operational momentum Second-qua...
Q1 2026 Group performance Comparable order intake growth 6% Group sales of EUR 3.9 billion, reflecting 4% increase in comparable sales Income ...
Financial performance Q1 2026 reported sales increased by 32% at CER, positively impacted by a provision reversal related to the 340B Drug Prici...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended Ma...
"In the first quarter, Samsung Biologics delivered stable growth, supported by consistent execution across our manufacturing network and continued demand f...
Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its co...
Total fourth quarter revenue of $878 million, an increase of 23% on a reported and core revenue basis, with Screening revenue of $695 million and Pre...
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, announced financial results for the fourth quarte...
Product Sales Excluding Veklury Increased 4% Year-Over-Year to $28.0 billion for Full Year 2025 Biktarvy Sales Increased 7% Year-Over-Year to $1...
© 2026 Biopharma Boardroom. All Rights Reserved.
